ArticleThe Indian journal of medical research2026
Immunohistochemical evaluation of glutaminase-1 enzyme in oral squamous cell carcinoma.
Article in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Malignant cells reprogram their metabolism. Glutamine is a major biosynthetic precursor apart from glucose in various cancers. Glutaminase 1 (kidney type) is the rate limiting enzyme in glutamine metabolism, which is increased in cancers of prostate, breast, colorectum, ovary and oral squamous cell. We aimed to evaluate the intensity and extent of immunohistochemical expression of glutaminase1 in various grades of oral squamous cell carcinoma (OSCC) and investigate whether any association exists between the glutaminase 1expression with staging, grading and tumour infiltrating lymphocytes. Methods This retrospective analysis included 98 formalin-fixed, paraffin-embedded tissue blocks of clinically and histopathologically confirmed cases of OSCC. One section was stained with haematoxylin and eosin and the other, immunohistochemically for glutaminase 1(GLS1). Staging, grading, tumour infiltrating lymphocytes were evaluated for their relation with GLS1 immunoscore. Results Statistically significant association was noted between GLS1 immunointensity (P<0.001) immunoextent (P<0.001) and the immunoscore (P=0.007) with the worsening grades of OSCC. There was no significant association between TNM staging P<0.61) and tumour infiltrating lymphocytes with GLS1 immunoscore (P=0.30). Interpretation and conclusions Glutaminase 1 expression increases with worsening grade of OSCC signifying an altered metabolic phenotype as the cancer cells lose differentiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.